Cibus Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Los beneficios de Cibus han disminuido a una tasa media anual de -23.5%, mientras que en la industria Biotechs los beneficios crecieron en un 12.7% anualmente. Los ingresos han ido disminuyendo a una tasa media de 2.5% al año.
Información clave
-38.6%
Tasa de crecimiento de los beneficios
26.4%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 17.0% |
| Tasa de crecimiento de los ingresos | -12.1% |
| Rentabilidad financiera | -112.3% |
| Margen neto | -12,313.3% |
| Última actualización de beneficios | 31 Mar 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Cibus: Expanding Opportunities And Growing Accessible Market
Jan 12Is Cibus, Inc. (NASDAQ:CBUS) Trading At A 44% Discount?
Oct 19
Does Cibus (NASDAQ:CBUS) Have A Healthy Balance Sheet?
Sep 07Calyxt signs agreement with Evologic to scale production of plant-based ingredients
Oct 07Calyxt exploring strategic alternatives
Sep 22Calyxt Switches Gears Again, But The Cash Clock Keeps Ticking Down
Apr 01Calyxt Needs To Secure More Commercial Partners As Cash Dwindles
Sep 16Will Calyxt (NASDAQ:CLXT) Spend Its Cash Wisely?
Aug 17Analysts Just Shaved Their Calyxt, Inc. (NASDAQ:CLXT) Forecasts Dramatically
May 11Calyxt, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 08Is Calyxt (NASDAQ:CLXT) A Risky Investment?
Apr 30Calyxt, Inc. (NASDAQ:CLXT) Analysts Just Cut Their EPS Forecasts Substantially
Mar 09Here's What Calyxt, Inc.'s (NASDAQ:CLXT) Shareholder Ownership Structure Looks Like
Feb 25Desglose de ingresos y gastos
Cómo gana y gasta dinero Cibus. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Mar 24 | 2 | -286 | 21 | 45 |
| 31 Dec 23 | 2 | -268 | 16 | 36 |
| 30 Sep 23 | 1 | -53 | 13 | 25 |
| 30 Jun 23 | 0 | -33 | 11 | 14 |
| 31 Mar 23 | 0 | -17 | 10 | 11 |
| 31 Dec 22 | 0 | -17 | 11 | 12 |
| 30 Sep 22 | 2 | -21 | 14 | 12 |
| 30 Jun 22 | 10 | -22 | 14 | 12 |
| 31 Mar 22 | 22 | -25 | 14 | 11 |
| 31 Dec 21 | 26 | -29 | 15 | 11 |
| 30 Sep 21 | 38 | -36 | 16 | 12 |
| 30 Jun 21 | 35 | -38 | 17 | 11 |
| 31 Mar 21 | 26 | -44 | 19 | 11 |
| 31 Dec 20 | 24 | -45 | 21 | 11 |
| 30 Sep 20 | 14 | -44 | 23 | 11 |
| 30 Jun 20 | 11 | -45 | 25 | 12 |
| 31 Mar 20 | 10 | -43 | 26 | 12 |
| 31 Dec 19 | 7 | -40 | 25 | 12 |
| 30 Sep 19 | 4 | -36 | 25 | 11 |
| 30 Jun 19 | 1 | -33 | 23 | 11 |
| 31 Mar 19 | 0 | -31 | 20 | 12 |
| 31 Dec 18 | 0 | -28 | 18 | 10 |
| 30 Sep 18 | 0 | -26 | 16 | 10 |
| 30 Jun 18 | 0 | -32 | 19 | 13 |
| 31 Mar 18 | 0 | -28 | 16 | 11 |
| 31 Dec 17 | 1 | -26 | 15 | 12 |
| 30 Sep 17 | 0 | -24 | 13 | 11 |
| 30 Jun 17 | 0 | -13 | 8 | 6 |
| 31 Mar 17 | 0 | -12 | 7 | 6 |
| 31 Dec 16 | 0 | -12 | 7 | 6 |
| 31 Dec 15 | 1 | -6 | 4 | 3 |
Ingresos de calidad: CBUS is currently unprofitable.
Margen de beneficios creciente: CBUS is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: CBUS is unprofitable, and losses have increased over the past 5 years at a rate of 38.6% per year.
Acelerando crecimiento: Unable to compare CBUS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: CBUS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Rentabilidad financiera
Alta ROE: CBUS has a negative Return on Equity (-112.32%), as it is currently unprofitable.